BA
Therapeutic Areas
Savara Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Molgramostim Nebulizer Solution (Molgradex®) | Autoimmune Pulmonary Alveolar Proteinosis (aPAP) | Phase 3 |
| Molgramostim Nebulizer Solution | Non-tuberculous mycobacterial (NTM) Lung Infection in Cystic Fibrosis | Phase 2 |
Leadership Team at Savara
RN
Rob Neville
Chief Executive Officer
DL
David Lowrance
Chief Financial Officer
MP
Matt Pauls
Chief Business Officer
RJ
Raymond J. Hage, Jr.
Chief Executive Officer of Serendex Pharmaceuticals (subsidiary)
JT
John T. Potts
Chief Medical Officer
DR
David Ramsay
Chairman of the Board
AM
Amit Munshi
Director
RE
Rick E Winningham
Director
MG
Mikael G. Widell
Director
JH
John H. Johnson
Director